## **RT-PCR primers**

h-Egr-1	
forward	5'-GACCCGTTCGGATCCTTTCC-3'
reverse	5'-GCCACAAGGTGTTGCCACTG-3'
h-Actin	
forward	5'-GGCGGCAACACCATGTACCCT-3'
reverse	5'-AGGGGCCGGACTCGTCATACT-3'
h-EGFR	
forward	5' AAC ACC CTG GTC TGG AAG TAC 3'
reverse	5' ACA CCA GTT GAG CAG GTA CTG 3'
h-p53	

forward 5' TGGAAACTACTTCCTGAAAACAAC 3' reverse 5' AGTCAGGCCCTTCTGTCTTG 3'

**Supplement Figure S1. Sequence of primers used for RT-PCR.** Human Egr-1, actin and EGFR primers were designed using Primer3 software. Human p53 primers were from: Avery-Kiejda KA. et al, Clin. Cancer Res. 2008; 14:1659-68.

## ChIP primers

h-*EGR1* promoter, p53 binding site A3 [1] forward 5'-GGCCCCGGCGGCGGCGGCTAGAGCTCTAGGCTT-3' reverse 5'-GCGGCTCCCCAAGTTCTGCG-3'

h-*EGR1* promoter, p53 binding site A2 [1] forward 5'-TGACAGCGATAGAACCCCGGCCCGACTCGC reverse 5'-CGTTGCCCCTCCCTCCGCCTTCTTCCCTCC

h-*TP53* promoter, Egr-1 binding site [2] forward 5'-TGGGAGTTGTAGTCTGAACGCTTC-3' reverse 5'-GAGAAGCTCAAAACTTTTAGCGCC-3'

h-*EGFR* promoter, Egr1-Binding site (EBS) forward 5'-GGACCCGAATAAAGGAGCAG-3' reverse 5'-GAGGAGAATGCGAGGAGGAG-3'

**Supplement Figure S2. Sequence of primers used in ChIP experiments.** The first three primer pairs (*EGR1* promoter and *TP53* promoter) were from the indicated references [1] and [2].

The EBS in the *EGFR* promoter was described in [3]. Primers were designed using Primer3 software to amplify the DNA fragment surrounding the EBS.

[1] Yu J, Baron V, Mercola D, Mustelin T, Adamson ED. A network of p73, p53 and Egr1 is required for efficient apoptosis in tumor cells. Cell Death Differ 2007;14:436-46.

[2] Krones-Herzig A, Mittal S, Yule K, *et al.* Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 2005;65:5133-43.

[3] Nishi H, Nishi KH, Johnson AC. Early Growth Response-1 gene mediates upregulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002;62:827-34.





**Supplement Figure S3:** Correlation between Egr-1 and p53 expression in prostate cells. Protein expression was quantified by densitometric analysis of the autoradiograms. Egr-1 expression was plotted against p53 expression for each cell line. Correlation coefficient R=0.602 (left panel). When M12 cells were considered outsider and removed, the correlation coefficient was R=0.865 (right panel).



**Supplement Figure S4:** DU145 cells were treated with Pifithrin- $\alpha$  (20  $\mu$ M) for 16 hrs, followed by FBS stimulation for 1 hr. Total RNA was purified from the cells and Egr-1 mRNA level was measured by semi-quantitative RT-PCR. Results were analyzed on 2% agarose gels containing Ethidium Bromide.



Supplement Figure S5: Effect of p53 inhibitor pifithrin- $\alpha$  on Egr-1 protein expression in mouse fibroblasts. Mouse Embryo Fibroblasts (MEF) were a gift from Prof. Dan Mercola (UC Irvine) and have been described in (Krones-Herzig et al, PNAS 2003; 100:3233). These cells were used at late passage (P44) and contain mutant p53. NIH3T3 cells, in contrast, contain wild-type p53. Cells were treated with 30  $\mu$ M pifithrin- $\alpha$  for the indicated times, lysed, and analyzed by Western Blot. It can be noted that in contrast to human prostate cancer cells, pifithrin- $\alpha$  decreased the level of p53 in both fibroblast cell lines.



**Supplement Figure S6:** PC3 and 22Rv1 cells were transfected with wt-p53 or with the indicated mutant p53. Two days after transfection, total RNA was purified from the cells and mRNA levels were measured by semi-quantitative RT-PCR. Results were analyzed on 2% agarose gels containing Ethidium Bromide.



**Supplement Figure S7:** PC3 and DU145 cells were treated with various growth factors or stress for 1 hour (eto: etoposide; UV: ultra-violet; FBS: fetal bovine serum), lysed, and Egr-1 protein level was analyzed by western blot.

Egr-1 expression was low in PC3, and could be induced only by TPA, though to a lesser extent than in DU145.



**Supplement Figure S8:** Cells were treated for PBS for 1 hour to allow for maximum Egr-1 induction. Protein expression and phosphorylation of ERK1/2 were measured by western blot using specific antibodies. We observe that PC3 cells, which have almost undetectable amount of Egr-1, also display weak phosphorylation of ERK1/2. In addition, PC3 cells were "resistant" to Egr-1 induction .



**Supplement Figure S9:** Cells were treated with cyclohexamide or with MEK inhibitor PD98059 for the indicated times. The experiments were analyzed by western blot using the indicated antibodies. Phosphorylation of ERK1/2 is shown as control for PD98059 efficacy. Egr-1 half-life was calculated from two similar experiments, T1/2 = 30 min.



Supplement Figure S10: Lack of effect of PDGF-R inhibitor on protein phosphorylation and growth of DU145. DU145 cells were treated with increasing concentrations of PDGF-R inhibitor or with DMSO. (A) Cells were lysed after 4hrs and the phosphorylation of ERK1/2 and AKT was visualized by Western Blot. (B) After 48hrs, cells were counted using the Cell Coulter Multisizer as described in the Methods. The experiment shown is representative of two similar experiments, each run in duplicates.

PDGF-R inhibitor (TK inhibitor III) was purchased from Calbiochem (EMD Biosciences, San Diego, CA).